What is Zacks Research's Estimate for NKTR FY2025 Earnings?

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Research analysts at Zacks Research issued their FY2025 EPS estimates for Nektar Therapeutics in a report released on Monday, June 30th. Zacks Research analyst K. Das expects that the biopharmaceutical company will post earnings of ($8.76) per share for the year. The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share.

Other analysts have also issued research reports about the stock. Oppenheimer raised shares of Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $90.00 price target on the stock in a research report on Friday, March 14th. BTIG Research upped their price objective on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, June 24th. Jefferies Financial Group raised Nektar Therapeutics from a "hold" rating to a "buy" rating and increased their target price for the company from $15.00 to $30.00 in a research note on Friday, April 11th. HC Wainwright lifted their price objective on Nektar Therapeutics to $120.00 and gave the stock a "buy" rating in a research report on Tuesday, June 24th. Finally, William Blair reiterated a "market perform" rating on shares of Nektar Therapeutics in a report on Monday, May 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $84.17.

Nektar Therapeutics Price Performance

Shares of NKTR traded down $0.88 during mid-day trading on Thursday, hitting $24.65. The stock had a trading volume of 994,109 shares, compared to its average volume of 476,131. The firm has a market cap of $305.91 million, a P/E ratio of -2.57 and a beta of 0.94. The business has a fifty day moving average price of $12.97 and a 200-day moving average price of $12.56. Nektar Therapeutics has a 52 week low of $6.48 and a 52 week high of $37.38.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) EPS for the quarter, missing analysts' consensus estimates of ($2.70) by ($0.60). The company had revenue of $10.46 million during the quarter, compared to the consensus estimate of $15.61 million. Nektar Therapeutics had a negative return on equity of 329.54% and a negative net margin of 152.49%. During the same period last year, the firm posted ($2.70) EPS.

Institutional Trading of Nektar Therapeutics

A number of hedge funds have recently modified their holdings of the business. Voya Investment Management LLC boosted its stake in Nektar Therapeutics by 46.8% during the first quarter. Voya Investment Management LLC now owns 266,773 shares of the biopharmaceutical company's stock worth $181,000 after acquiring an additional 85,094 shares in the last quarter. Rhumbline Advisers boosted its stake in Nektar Therapeutics by 23.3% during the first quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company's stock worth $151,000 after acquiring an additional 41,948 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Nektar Therapeutics by 1.4% in the 1st quarter. Acadian Asset Management LLC now owns 7,301,734 shares of the biopharmaceutical company's stock worth $4,961,000 after purchasing an additional 100,645 shares in the last quarter. Fred Alger Management LLC bought a new stake in shares of Nektar Therapeutics in the 1st quarter worth approximately $344,000. Finally, Integrated Wealth Concepts LLC bought a new stake in shares of Nektar Therapeutics in the 1st quarter worth approximately $68,000. Institutional investors own 75.88% of the company's stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.